Канал: David Lauren Research | Oncology in 3 minutes.

Risk of Second Tumors and T-Cell Lymphoma after CAR-T Cell Therapy

Risk of Second Tumors and T-Cell Lymphoma after CAR-T Cell Therapy

Perioperative Nivolumab in Resectable Lung Cancer

Perioperative Nivolumab in Resectable Lung Cancer

[57] Chemoprevention of head and neck cancer with green tea polyphenols

[57] Chemoprevention of head and neck cancer with green tea polyphenols

[55] Perspectives for cancer prevention with natural compounds

[55] Perspectives for cancer prevention with natural compounds

[54] Cancer phase I clinical trials: efficient dose escalation with overdose control

[54] Cancer phase I clinical trials: efficient dose escalation with overdose control

[53] Flexible Bayesian methods for cancer phase I trials. Dose escalation with overdose control

[53] Flexible Bayesian methods for cancer phase I trials. Dose escalation with overdose control

[52] EGFR-targeted therapy with C225 and cisplatin in patients with head and neck cancer

[52] EGFR-targeted therapy with C225 and cisplatin in patients with head and neck cancer

[50] Phase I and pharmacologic study of OSI-774, an EGFR TKI, for advanced solid malignancies

[50] Phase I and pharmacologic study of OSI-774, an EGFR TKI, for advanced solid malignancies

[49] Targeting EGFR: integration of novel therapeutics in the management of H&N cancer

[49] Targeting EGFR: integration of novel therapeutics in the management of H&N cancer

[48] activation of Stat3 signaling abrogates apoptosis in squamous cell carcinogenesis in vivo

[48] activation of Stat3 signaling abrogates apoptosis in squamous cell carcinogenesis in vivo

[47] Requirement of Stat3 but not Stat1 activation for EGFR-mediated cell growth In vitro

[47] Requirement of Stat3 but not Stat1 activation for EGFR-mediated cell growth In vitro

[46] Pharmacokinetics and variability of green tea catechins and EGCG metabolites in humans

[46] Pharmacokinetics and variability of green tea catechins and EGCG metabolites in humans

[45] Green tea catechins on prostate cancer prevention in high-grade PIN patients: a 1-year trial

[45] Green tea catechins on prostate cancer prevention in high-grade PIN patients: a 1-year trial

[44] Hepatotoxicity associated with supplements containing Chinese green tea

[44] Hepatotoxicity associated with supplements containing Chinese green tea

[43] A receptor for green tea polyphenol EGCG

[43] A receptor for green tea polyphenol EGCG

[42] Ablation of either p21 or Bax prevents p53-dependent apoptosis induced by EGCG

[42] Ablation of either p21 or Bax prevents p53-dependent apoptosis induced by EGCG

[41] EGCG decreases VEGF production in h&N and breast cancer cells by innhibiting EGFR pathways

[41] EGCG decreases VEGF production in h&N and breast cancer cells by innhibiting EGFR pathways

[40] Inhibition of Tumor Promoter-Induced Cell Transformation by Tea Polyphenols: EGCG & Theaflavins

[40] Inhibition of Tumor Promoter-Induced Cell Transformation by Tea Polyphenols: EGCG & Theaflavins

[39] EGCG Effects on Growth, EGFR Signaling, Gene Expression & Chemosensitivity in HNSCC Cells

[39] EGCG Effects on Growth, EGFR Signaling, Gene Expression & Chemosensitivity in HNSCC Cells

[38] EGCG blocks HER-2/neu and related pathways in H&N, Breast cancer cells

[38] EGCG blocks HER-2/neu and related pathways in H&N, Breast cancer cells

[lung] Afatinib vs cisplatin chemo for EGFR+ lung cancer: survival data from LUX-Lung trials

[lung] Afatinib vs cisplatin chemo for EGFR+ lung cancer: survival data from LUX-Lung trials

[stomach] FLOT vs FLOT/TP for HER2+ Esophagogastric Cancer Trial

[stomach] FLOT vs FLOT/TP for HER2+ Esophagogastric Cancer Trial

[37] EGCG inhibits EGFR signaling pathway. Evidence for direct inhibition of ERK1/2 and AKT kinases

[37] EGCG inhibits EGFR signaling pathway. Evidence for direct inhibition of ERK1/2 and AKT kinases

[36] EGCG inhibit growth and activation of the EGFR and human HER-2 signaling pathways

[36] EGCG inhibit growth and activation of the EGFR and human HER-2 signaling pathways

[35] Molecular targets of dietary agents for prevention and therapy of cancer

[35] Molecular targets of dietary agents for prevention and therapy of cancer

[34] Combined inhibition of estrogen-dependent human breast carcinoma by soy and tea

[34] Combined inhibition of estrogen-dependent human breast carcinoma by soy and tea

[33] Green tea and its catechins inhibit breast cancer xenografts

[33] Green tea and its catechins inhibit breast cancer xenografts

[32] Blocking telomerase by dietary polyphenols, limiting the growth of cancer cells

[32] Blocking telomerase by dietary polyphenols, limiting the growth of cancer cells

[31] Growth inhibition and regression of human prostate and breast tumors in athymic mice by EGCG

[31] Growth inhibition and regression of human prostate and breast tumors in athymic mice by EGCG

[30] Growth inhibitory and antimetastatic effect of green tea polyphenols on 4T1 cells

[30] Growth inhibitory and antimetastatic effect of green tea polyphenols on 4T1 cells

[29] A green tea polyphenol, EGCG, induces apoptosis of human HCC

[29] A green tea polyphenol, EGCG, induces apoptosis of human HCC

[28] The repressive effect of green tea ingredients on APP expression in oral carcinoma cells

[28] The repressive effect of green tea ingredients on APP expression in oral carcinoma cells

[27] Tea catechins and polyphenols: health effects, metabolism, and antioxidant functions

[27] Tea catechins and polyphenols: health effects, metabolism, and antioxidant functions

[26] Green tea and cancer in humans a review of the literature

[26] Green tea and cancer in humans a review of the literature

[25] Cancer rates among drinkers of Black tea

[25] Cancer rates among drinkers of Black tea

[24] Green tea and risk of breast cancer in Asian Americans

[24] Green tea and risk of breast cancer in Asian Americans

[23] Influence of drinking green tea on breast cancer

[23] Influence of drinking green tea on breast cancer

[22] Cancer preventive effects of drinking green tea among a Japanese population

[22] Cancer preventive effects of drinking green tea among a Japanese population

[21] Tumor growth inhibition by simultaneously blocking EGFR and COX-2 in a xenograft model

[21] Tumor growth inhibition by simultaneously blocking EGFR and COX-2 in a xenograft model

[20] Simultaneously targeting EGFR-TK and COX-2, an efficient approach to inhibition of sqcc of H&N

[20] Simultaneously targeting EGFR-TK and COX-2, an efficient approach to inhibition of sqcc of H&N

[19] COX-2: a novel molecular target for the prevention and treatment of head and neck cancer

[19] COX-2: a novel molecular target for the prevention and treatment of head and neck cancer

[18] Inhibition of cox-2 expression An approach to preventing head and neck cancer

[18] Inhibition of cox-2 expression An approach to preventing head and neck cancer

[17] Biochemoprevention for dysplastic lesions of the upper aerodigestive tract

[17] Biochemoprevention for dysplastic lesions of the upper aerodigestive tract

[16] Combined interferon alfa13 cis retinoic acid and alpha tocopherol in locally advanced

[16] Combined interferon alfa13 cis retinoic acid and alpha tocopherol in locally advanced

[15] Randomized phase III trial of low dose isotretinoin for prevention of second primary tumors

[15] Randomized phase III trial of low dose isotretinoin for prevention of second primary tumors

[14] Low dose isotretinoin versus beta carotene to prevent oral carcinogenesis long term follow up

[14] Low dose isotretinoin versus beta carotene to prevent oral carcinogenesis long term follow up

[13] Comparison of low-dose isotretinoin with beta carotene to prevent oral carcinogenesis,1993 NEJM

[13] Comparison of low-dose isotretinoin with beta carotene to prevent oral carcinogenesis,1993 NEJM

[12] 13-cis-retinoic acid in the treatment of oral leukoplakia (1986 NEJM)

[12] 13-cis-retinoic acid in the treatment of oral leukoplakia (1986 NEJM)

[10] what is HEAD and NECK cancer?

[10] what is HEAD and NECK cancer?

[11]Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention

[11]Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention

[9] Phase Ib Study of Chemoprevention with Green Tea Polyphenon E and Erlotinib-

[9] Phase Ib Study of Chemoprevention with Green Tea Polyphenon E and Erlotinib-

[8] The Erlotinib Prevention of Oral Cancer (EPOC) Randomized Clinical Trial

[8] The Erlotinib Prevention of Oral Cancer (EPOC) Randomized Clinical Trial

[7] Combination of erlotinib and EGCG induces apoptosis of head and neck cancers through-

[7] Combination of erlotinib and EGCG induces apoptosis of head and neck cancers through-

[6] simultaneous blocking of EGFR and cyclooxygenase-2 signaling pathway, chemoprevention of HNC

[6] simultaneous blocking of EGFR and cyclooxygenase-2 signaling pathway, chemoprevention of HNC

[5] Cancer prevention with natural compounds

[5] Cancer prevention with natural compounds

[4] Oral cancer prevention advances with a translational trial of green tea

[4] Oral cancer prevention advances with a translational trial of green tea

[3] Role of cyclooxygenase 2 in tumor progression

[3] Role of cyclooxygenase 2 in tumor progression

[2] Synergistic growth inhibition of sqcc of the head and neck by erlotinib and EGCG

[2] Synergistic growth inhibition of sqcc of the head and neck by erlotinib and EGCG

[1] Phase I trial of oral green tea extract in adult patients with solid tumors

[1] Phase I trial of oral green tea extract in adult patients with solid tumors

[lung] Selpercatinib 2022, subset analysis of a Global Phase 1/2

[lung] Selpercatinib 2022, subset analysis of a Global Phase 1/2

[skin] Effects of cemiplimab used before skin cancer surgery

[skin] Effects of cemiplimab used before skin cancer surgery

[lung] Selpercatinib, Patient-reported outcomes (2022 Feb Oncologist)

[lung] Selpercatinib, Patient-reported outcomes (2022 Feb Oncologist)

[thyroid] selpercatinib & effusion, adverse events

[thyroid] selpercatinib & effusion, adverse events

[lung] Selpercatinib (LOXO-292) being given to the lung cancer patient for the first time

[lung] Selpercatinib (LOXO-292) being given to the lung cancer patient for the first time

[lung] Selpercatinib is also effective against brain metastasis.

[lung] Selpercatinib is also effective against brain metastasis.

[lung] Effect of selpercatinib for RET-positive patients

[lung] Effect of selpercatinib for RET-positive patients

[pancreas] Preoperative mFOLFIRINOX vs chemoradiation, who wins?

[pancreas] Preoperative mFOLFIRINOX vs chemoradiation, who wins?

[pancreas] What is the winner of chemotherapy after surgery for pancreatic cancer?

[pancreas] What is the winner of chemotherapy after surgery for pancreatic cancer?

[GIST] Did Ripretinib beat Sunitinib in GIST?

[GIST] Did Ripretinib beat Sunitinib in GIST?

[pancreas] I received neoadjuvant chemotherapy, do I need adjuvant chemotherapy again?

[pancreas] I received neoadjuvant chemotherapy, do I need adjuvant chemotherapy again?

[prostate] Can eating lots of vegetables prevent prostate cancer at my age?

[prostate] Can eating lots of vegetables prevent prostate cancer at my age?

[colorectal] Does blood PCR help predict recurrence of colorectal cancer?

[colorectal] Does blood PCR help predict recurrence of colorectal cancer?

[kidney]What is the strongest player in kidney cancer treatment after 2018?

[kidney]What is the strongest player in kidney cancer treatment after 2018?

[lung]Postoperative role of erlotinib in patients with EGFR mutation-positive stage 3 lung cancer.

[lung]Postoperative role of erlotinib in patients with EGFR mutation-positive stage 3 lung cancer.

[pancreas] Role of olaparib in stage 4 pancreatic cancer patients with BRCA mutations

[pancreas] Role of olaparib in stage 4 pancreatic cancer patients with BRCA mutations

[lung]The role of durvalumab in patients with stage 3 lung cancer in a real hospital

[lung]The role of durvalumab in patients with stage 3 lung cancer in a real hospital

[lymphoma] After Polatuzumab and CAR-T appeared, Lymphoma Treatment Cost Concerns

[lymphoma] After Polatuzumab and CAR-T appeared, Lymphoma Treatment Cost Concerns